Personalis (PSNL) Expected to Post Earnings on Tuesday

Personalis (NASDAQ:PSNL) is expected to be announcing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.2633) per share and revenue of $21.54 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 5:00 PM ET.

Personalis (NASDAQ:PSNL) last posted its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. The business had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million.

Personalis Stock Performance

Shares of NASDAQ PSNL opened at $15.88 on Tuesday. The firm has a 50 day moving average price of $16.27 and a two-hundred day moving average price of $11.17. The stock has a market cap of $1.66 billion, a P/E ratio of -14.57 and a beta of 2.32. Personalis has a 52-week low of $4.95 and a 52-week high of $18.89.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on PSNL shares. BTIG Research downgraded Personalis from a “buy” rating to a “neutral” rating in a report on Tuesday, October 6th. Craig Hallum downgraded Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price on the stock. in a report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Thursday, October 15th. Morgan Stanley increased their price target on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Finally, Zacks Research upgraded Personalis from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Three investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $14.54.

Insider Activity

In other Personalis news, CEO Christopher M. Hall sold 7,459 shares of the stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.22, for a total transaction of $120,984.98. Following the completion of the sale, the chief executive officer directly owned 228,527 shares in the company, valued at approximately $3,706,707.94. This trade represents a 3.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Richard Chen sold 3,998 shares of Personalis stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $64,847.56. Following the completion of the transaction, the chief marketing officer directly owned 169,882 shares of the company’s stock, valued at approximately $2,755,486.04. This trade represents a 2.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 16,456 shares of company stock worth $266,916 in the last three months. Corporate insiders own 4.20% of the company’s stock.

About Personalis

Personalis, Inc is a genomics company focused on applying advanced sequencing and bioinformatics to cancer research and precision medicine. The company develops tests and data platforms designed to help researchers and clinicians characterize tumors, monitor disease, and support the development of targeted therapies.

Its product portfolio includes the NeXT Platform, which analyzes tumor and normal DNA and RNA to provide a detailed view of cancer biology, as well as products such as NeXT Dx, NeXT Liquid Biopsy, and NeXT Personal.